Drugs / PROHIBITIN-TP01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01262664 | May 2012 → Jan 2019 | prostate cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-01-04 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial arrowheadpharma.com ↗
today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, AdipotideTM, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-01-04 | Arrowhead Pharmaceuticals | Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial arrowheadpharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prohibitin-TP01 | “Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.” NCT01262664 ↗ |
| Known as | Prohibitin Targeting Peptide 1 | “A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity” NCT01262664 ↗ |
| Modality | Peptide | “Prohibitin Targeting Peptide 1” NCT01262664 ↗ |
| Route | Subcutaneous | “as an injection under the skin” NCT01262664 ↗ |